The nervous system doesn’t wait.
It reacts in milliseconds. That speed is a feature for your body. For clinical trials? It’s usually a nightmare of lost data. Kordata Dynamics just emerged from stealth. They are chasing a $26 billion problem.
Most Central Nervous System (CNS) trials are stuck. Backlogged. Slow.
Kordata says it will fix this with two things. Patient-facing neurotech. An enterprise playbook. It sounds simple. The execution is not.
BIOS Health handed them the core IP. BIOS still owns most of the new company. They share a founder, Emil Hewage. He’s now CEO. Working with him is Dawn McCollough. She ran 15,000 trials at Biogen and Novartis. You’d expect them to know their way around a protocol.
I spoke with Hewage. I wanted to know how they move neural data from the patient into the pharma pipeline.
The Model Isn’t Just Hardware
Kordata partners with big health systems. Academic medical centers.
These hospitals have patients. Lots of them. But they lack the tech to run modern trials. They have capacity but no capability. Standard EMR systems can’t handle novel neural data streams. IRB compliance gets in the way.
Kordata plugs into that gap.
They charge licensing fees to deploy tools across these hospital networks. They also take fees on new trial sponsorships at partner sites. It’s volume-based. If they help you run more trials. You pay.
Who Are They Helping?
Not everyone.
Hewage targets firms with precise products. Tight dosing ranges. Weird inclusion criteria. He wants the companies designing novel trials that traditional CROs can’t touch.
“The nervous system is the fastest things to react in your body.”
It starts with Alzheimer’s. Parkinson’s. Epilepsy. But the scope widens fast. Cardiology. Immunology. Chronic diseases that don’t respond to old drugs.
Real-Time Decoding
The tech stack runs on NeuroTune. This is BIOS’ proprietary engine.
It adjusts dosing in real time. Based on how an individual reacts.
Wearables or implanted devices send the signal. The system captures organ and brain responses at the millisecond mark. Partner sites use this to characterize reactions before the side effects become irreversible or the window for data closes.
Plug and play. Sort of.
Why Bakersfield?
Most neurotech launches happen in SF or Boston. Kordata picked Bakersfield. CA.
Hewage didn’t just pick it because rent is lower. There is an established network of public payers there. The patients work in every industry. Every socioeconomic bracket.
It’s an ideal recruitment ground. Real people. Not just the tech-savvy early adopters usually seen in trial demographics.
The launch room had leaders from the Royal College of Surgesons. NVIDIA execs. Municipal leaders. Investors included Kern Venture Group, MAVRK Celeistia Fund, and Digital Neural Infrasrtucture Holdings.
Neurotech promises to improve drug discovery. It has promised that for a decade. Historically inertia won. Legacy tools won.
AI is forcing things to move now. Kordata bet that the time was right.
We’ll see if the data travels fast enough to matter.
